NRSN · NeuroSense Therapeutics Ltd.
Market Cap
$16.58M
Shares
37.77M
The company's filings as submitted to the SEC's EDGAR system — 10-K, 10-Q, 8-K, proxy statements and more — listed most recent first.
| Type | Filing Date | Period | Open |
|---|---|---|---|
| 6-K | 2026-08-27 | — | |
| 6-K | 2026-08-13 | — | |
| 6-K | 2026-08-06 | — | |
| 6-K | 2026-07-31 | — | |
| 6-K | 2026-07-31 | — | |
| 6-K | 2026-07-22 | — | |
| 6-K | 2026-06-29 | — | |
| 6-K | 2026-06-25 | — | |
| 6-K | 2026-06-11 | — | |
| 6-K | 2026-06-09 | — | |
| 6-K | 2026-06-08 | — | |
| 6-K | 2026-04-28 | — | |
| 6-K | 2026-04-24 | — | |
| 6-K | 2026-04-06 | — | |
| 6-K | 2026-04-03 | — | |
| 6-K | 2026-03-31 | — | |
| 20-F | 2026-03-31 | 2025-12-31 | |
| 6-K | 2026-03-24 | — | |
| 6-K | 2026-03-16 | — | |
| 6-K | 2026-03-11 | — | |
| 6-K | 2026-02-18 | — | |
| 6-K | 2026-02-13 | — | |
| 6-K | 2026-02-09 | — | |
| 6-K | 2026-01-06 | — | |
| 6-K | 2025-12-22 | — | |
| 6-K | 2025-12-08 | — | |
| 6-K | 2025-12-04 | — | |
| 6-K | 2025-11-24 | — | |
| 6-K | 2025-11-21 | — | |
| 6-K | 2025-10-06 | — | |
| 6-K | 2025-09-25 | — | |
| 6-K | 2025-09-10 | — | |
| 6-K | 2025-09-04 | — | |
| 6-K | 2025-09-04 | — | |
| 6-K | 2025-09-02 | — | |
| 6-K | 2025-08-21 | — | |
| 6-K | 2025-08-20 | — | |
| 6-K | 2025-08-01 | 2025-06-30 | |
| 6-K | 2025-07-10 | — | |
| 6-K | 2025-06-26 | — | |
| 6-K | 2025-05-07 | — | |
| 6-K | 2025-04-24 | — | |
| 20-F | 2025-04-07 | 2024-12-31 | |
| 6-K | 2025-04-07 | — | |
| 6-K | 2025-03-27 | — | |
| 6-K | 2025-03-19 | — | |
| 6-K | 2025-02-19 | — | |
| 6-K | 2025-01-06 | — | |
| 6-K | 2024-12-23 | — | |
| 6-K | 2024-12-18 | — |
Showing 1–50 of 172 filings
Key facts
CIK
1875091
CUSIP
M74240108
13F (30d)
12 filings
12 filers
Visit website
Investor relations